Digestive diseases and sciences
-
Randomized Controlled Trial Comparative Study
Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease.
Infliximab is effective treatment for Crohn's disease and has been associated with rare, but serious infectious complications. Emerging data suggest a benefit of infliximab in preventing postoperative Crohn's disease recurrence. It is not known whether administration of infliximab shortly after resective surgery for Crohn's disease increases postoperative complications. ⋯ Initiation of infliximab within 4 weeks of intestinal resection was not associated with postoperative complications.